Your impact is real.
‍But buyers don’t know how to value it.

Clinical outcomes get companies to the table. They don’t close the deal. Reimbursement lags, buyers need economics, and early stories stop landing. If you can’t translate impact into value they can quantify, it gets discounted.

Find out where you're being discounted

The reality of women’s health today

Demand is strong, but reimbursement pathways lag clinical evidence
Clinical outcomes are clear before economic models are proven
Categories often require ongoing market education just to close standard deals
Buyers evaluate both impact and defensibility, and weight the latter heavily
Mission-driven positioning resonates internally but doesn’t always translate to enterprise buyers

If any of this is true, you have a credibility gap:

Your outcomes are strong, but hard to tie directly to ROI
Your story resonates emotionally, but not commercially
Payers are interested but hesitant. Adoption is slower than demand suggests.
Growth feels real from the inside but fragile under external scrutiny

Where growth breaks

What drives early traction — mission, clinical credibility, category passion — doesn’t scale into enterprise value. Early champions buy the vision. Later-stage buyers need economics and proof that doesn’t require a guided tour.

Payers ask questions the clinical team can’t answer in commercial terms. Investors want the growth model, not just outcomes data. The narrative that worked early starts creating hesitation exactly when you need it creating confidence.

From the inside, growth feels real. From the outside, it feels uncertain. And uncertainty gets discounted.

What buyers are really evaluating

Can this translate into measurable economic value, not just clinical impact?
Will payers support this long-term, or is reimbursement fragile?
Can this scale without constant market education?
Is the growth model transferable, or does it depend on founder relationships?
Does the proof hold up under diligence, or does it rely on anecdote?

Strong impact.
Undervalued company.

That’s the risk when clinical strength isn’t translated into a story buyers can underwrite.

How we help: Speed. Clarity. Impact.

We’ve worked across women’s health companies from early traction through exit. Our work closes the gap between the value you’ve built and what the market actually rewards.

We don’t generalize into this space. We operate inside it.

Translate impact into enterprise value

Reframe clinical outcomes in the economic language buyers use to evaluate acquisitions, without oversimplifying what makes your work credible.

Build proof that holds up

Align clinical, economic, and operational evidence into a structure buyers can validate quickly. Proof that requires explanation is proof that creates doubt.

Align growth to enterprise value

Connect brand, GTM, and leadership narrative so your growth becomes transferable, defensible, and independent of relationships or institutional memory.

Why Legacy DNA

We translate clinical impact into investor-ready value — not marketing copy.
We’re built around how acquirers actually evaluate risk in complex healthcare categories.
We’ve guided multiple healthcare companies through exit — we know what breaks under diligence.
Senior-led throughout. We don’t delegate the work that matters.
BioPlus Growth Story
A specialty pharmacy navigating commoditization pressure — where narrative clarity and proof alignment materially improved buyer confidence and valuation outcome.
→ View the full story

Who this is for

Strong fit

Mid-market women’s health companies scaling or preparing for exit
VC-backed or PE-owned businesses under pressure to explain and defend growth
Leadership teams where the clinical story is strong but the commercial story isn’t landing
Companies preparing for diligence where proof needs to hold up without the founder in the room

Not a fit

Early-stage companies still finding product-market fit
Teams looking for execution-only marketing support
Organizations not ready to examine how buyers will evaluate economic value

Find out where your business is being discounted

In 30 minutes, we’ll show you exactly where buyers lose confidence and where clarity could change the outcome. We’ll identify where your narrative creates valuation risk, surface a key gap likely to appear in diligence, and show you where alignment could unlock growth.
Book my Strategic Fit Call

FAQs

01

Why do women’s health companies struggle to scale despite strong demand?
Demand isn’t the constraint — translation is. Buyers evaluate risk, proof, and transferability. Strong outcomes without a commercial narrative create a gap that slows growth.

02

What do investors and acquirers look for in women’s health companies?
Clarity, credible proof, and a repeatable growth model. They want to know that your positioning is defensible, that outcomes are independently verifiable, and that the business scales without founder dependence.

03

How do you increase valuation in a women’s health company?
By closing the gap between clinical impact and economic narrative. Valuation improves when buyers can quickly understand what you’ve built and see a growth model that doesn’t depend on the people who built it.

04

Why does early messaging stop working as companies scale?
Early traction comes from mission and innovation. Later-stage buyers need evidence, economics, and less ambiguity. If the narrative doesn’t evolve, it creates friction exactly when you need it creating confidence.

05

When should a women’s health company invest in commercialization strategy?
Before growth stalls or exit pressure increases. Addressing the economic translation gap early reduces risk and gives you more leverage during scale or acquisition.